New Ebola treatment effective three days after infection.

A post-exposure treatment that is effective against a specific strain of the Ebola virus that killed thousands of people in West Africa has been developed by researchers. The treatment uses a sequence specific short strand of RNA, known as siRNA, designed to target and interfere with the Ebola virus, rendering it harmless. One of the advantages of this approach is the ability to quickly modify it to different viral strains. Although all infected animals showed evidence of advanced disease, those receiving treatment had milder symptoms and recovered fully. The untreated controls succumbed to the disease on days eight and nine, which is similar to that reported in the field after patients begin showing symptoms of Ebola. This treatment also protected against liver and kidney dysfunction and blood disorders that occur during an Ebola infection. These results indicate that the treatment may confer protective benefits that go beyond improving survival rates and effective control of virus levels in the body. This study demonstrates that we can rapidly and accurately adapt our siRNA-LNP technology to target genetic sequences emerging from new Ebola virus outbreaks," said Dr. Mark Murray, president and CEO of Tekmira Pharmaceuticals. The Tekmira siRNA-based therapeutic was used in Ebola-infected patients in Sierra Leone during the outbreak. Excerpts from papers of University of Texas Medical Branch at Galveston.